The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) plus rituximab (Rituxan) for the treatment of adult patients with Waldenström's macroglobulinemia (WM). With this approval, the ibrutinib prescribing information now includes combination use with rituximab,...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma. CPI-613 is a novel lipoic acid analog with an anticancer activity that inhibits multiple enzyme targets within the tricarboxylic acid cycle. This drug is...
Today, the U.S. Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. This approval provides a new...
Peggy Burhenn, MS, RN-BC, AOCNS, of the City of Hope National Medical Center, discusses the challenges of working with older lymphoma patients and the importance of effective geriatric assessments.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center and winner of this year’s Oliver Press Memorial Award, discuss three CAR T-cell products for lymphoma treatment, comparing their efficacy, toxicity, ease of ...
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatments that enhance progression-free and overall survival and clear minimal residual disease—obinutuzumab plus chemotherapy, lenalidomide, and rituximab—and the types of lymphoma patients who may benefit.
Bruce D. Cheson, MD, of Georgetown University Hospital, and Richard I. Fisher, MD, of Fox Chase Cancer Center, discuss ways to incorporate PET and CT scanning into standard of care for and research studies on lymphoma.
Philip J. Bierman, MD, of the University of Nebraska Medical Center, discusses how to identify and treat the 1% to 2% of patients with diffuse large B-cell lymphoma who have central nervous system involvement as well as systemic sites at the time of diagnosis.
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and those with comorbidities. Several strategies have been devised, but more research is needed as well as more options for novel...
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what could be the most effective treatments.
John G. Gribben, MD, DSc, of the Barts Cancer Institute, discusses how understanding the role of the tumor microenvironment can help identify treatment targets, including combination therapies, and improve outcome for patients with indolent lymphomas.
Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the efficacy of PD-1 blockade in Hodgkin lymphoma, new findings related to PD-1 therapy, current combination approaches, and future treatments.
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need for a proper support tool to help interpret the data.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to CPI-613 for the treatment of Burkitt lymphoma. Burkitt lymphoma is a highly aggressive hematologic B-cell malignancy classically characterized by the overexpression of c-Myc. Due to the rapid proliferation rate of...
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas. They also speculate that screening for a preexisting B-cell clone before starting therapy may help prevent this...
Positive interim data were recently presented from an ongoing phase II study of tazemetostat—a potent, selective, orally available EZH2 inhibitor—as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, presented by Salles et al at the 23rd Annual...
Fourteen-month results from the JULIET clinical trial showed ongoing durable responses are achievable with tisagenlecleucel (Kymriah) when administered to adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This updated analysis was presented by Borchmann et al at ...
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma or those who have relapsed after two or more prior lines of therapy. KEYNOTE-170...
The phase III iLLUMINATE (PCYC-1130) trial recently met its primary endpoint of improvement in progression-free survival. The study evaluated ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic...
On June 8, the U.S. Food and Drug Administration (FDA) granted regular approval to venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. MURANO Approval was based ...
Results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented by Fowler et al at the 2018 ASCO Annual Meeting (Abstract 7005). This study evaluated the investigational...
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).
Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on lenalidomide plus rituximab vs chemotherapy plus rituximab, followed by rituximab maintenance, in patients with ...
On May 1, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel (Kymriah) suspension for intravenous infusion for the treatment of adult patients with relapsed or refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and...
On April 9, the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review a new drug application (NDA) for the oral agent duvelisib, a first-in-class, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. The NDA is seeking full approval for duvelisib in...
On March 21, the U.S. Food and Drug Administration (FDA) issued updated information about its understanding of breast implant–associated anaplastic large cell lymphoma (ALCL). The agency is providing an updated number of medical device reports (ie, adverse event reports) and medical...
On March 20, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy. “Today’s approval represents an improvement in the initial...
New compounds targeting epigenetics have shown early activity in patients with lymphoma, according to data presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris. The meeting, which focused on phase I research, featured early clinical studies with BET inhibitors...
On March 6, Bristol-Myers Squibb announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the nivolumab (Opdivo) dosing schedule to include 480 mg infused every 4 weeks for a majority of approved indications. This approval will ...
Flora E. van Leeuwen, PhD, of the Netherlands Cancer Institute, discusses cardiovascular disease risk after treatment-induced primary ovarian insufficiency in female survivors of Hodgkin lymphoma (Abstract 114).
Today, the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for tisagenlecleucel (Kymriah) suspension for intravenous infusion (formerly CTL019) for the treatment of adult patients with relapsed or refractory diffuse large...
On January 2, the U.S. Food and Drug Administration (FDA) accepted for filing a supplemental Biologics License Application (sBLA) for brentuximab vedotin (Adcetris) in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin lymphoma. The FDA also...
On December 19, the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). The draft report, along with draft voting...
At the 59th American Society of Hematology (ASH) Annual Meeting & Exposition, Wang et al presented results from the open-label, single-arm phase II ACE-LY-004 clinical trial, which served as the basis for the recent U.S. Food and Drug Administration (FDA) accelerated approval of acalabrutinib...
Updated results from the phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris) in CD30-expressing cutaneous T-cell lymphoma (CTCL) were presented by Horwitz et al at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1509). The presentation...
In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration (FDA) found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in...
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with previously untreated stage III or IV Hodgkin lymphoma (Abstract 6).
Brian T. Hill, MD, PhD, of the Cleveland Clinic, discusses study findings that showed consolidation with autologous hematopoietic cell transplant in the first remission improves overall survival in patients younger than age 65 (Abstract 341).
Gilles A. Salles, MD, PhD, of the Université de Lyon, discusses study findings on rituximab maintenance after induction immunochemotherapy and the significant long-term progression-free survival benefit over observation (Abstract 486).
Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of HIV status (Abstract 188).
Jakub Svoboda, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses some encouraging phase I/II results on brentuximab vedotin with R-CHP chemotherapy as front-line treatment of CD30-positive primary mediastinal large B-cell, diffuse large B-cell, and gray zone lymphomas...
Andrew M. Evens, DO, of Tufts University, discusses findings on the effectiveness of DLBCL-based therapy for patients whose disease fell between diffuse large B-cell and classical Hodgkin lymphoma (Abstract 375).
Tycel J. Phillips, MD, of the University of Michigan Medical School, discusses the findings of the largest retrospective study to date of patients with intravascular diffuse large B-cell lymphoma, a disease with a poor outcome, partly due to the difficulty in diagnosing it early (Abstract 377).
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency and University of British Columbia, discusses long-term results of PET-guided radiation therapy in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP (Abstract 823).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss long-term study findings on axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma (Abstract 578).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephen J. Schuster, MD, of the Abramson Cancer Center, University of Pennsylvania, discuss phase II findings on tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma (Abstract 577).
Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).